Neurocrine Biosciences NBIX
NASDAQ NBIX
$141.32 +0.01 (+0.01%)
As of: Oct 22, 2026 · 10:35 AM EDT

Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2026)

Updated

Neurocrine Biosciences' Non-Current Deferred Tax Liability came in at $91.5 million for Q2 2026.

Analysis

Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,163.39 Bn 1,131.97 Bn 19.71 Bn
2 Johnson & Johnson 634.39 Bn 552.91 Bn 17.26 Bn
3 AbbVie 502.68 Bn 475.79 Bn 12.70 Bn
4 Merck 377.37 Bn 331.74 Bn 12.21 Bn
5 Novartis Ag 303.41 Bn 267.40 Bn 11.24 Bn
6 Astrazeneca 266.55 Bn 240.24 Bn 12.86 Bn
7 Amgen 240.56 Bn 195.96 Bn 7.24 Bn
8 Gilead Sciences 193.19 Bn 167.38 Bn 6.22 Bn
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn
10 Neurocrine Biosciences 14.27 Bn 9.97 Bn 935.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 91.50 Mn
API Access

Neurocrine Biosciences Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=NBIX&period=max&api_key=YOUR_API_KEY